BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:With TCEs being studied in both hematological and solid tumors
  (39 and 34 trials respectively)\, there are now more than one hundred pr
 ojects in the preclinical stage.Early clinical outcomes and novel TCE des
 ign modifications have fueled the development and clinical advancement of
  over 65 bispecific T-cell engagers (TCEs)\, which are presently in Phase
  I and Phase II investigations since the Cell Engager Series began.\n\nTh
 e 4th Annual Cell Engager Summit returns to bring you the latest on effec
 tively targeting lymphocyte-restricted tumor-associated antigens to treat
  hematological malignancies\, including CD19\, CD20\, BCMA\, CD33\, and C
 D123.Learn all there is to know about the immune cell engager landscape\,
  including clinical achievements\, potential response predictors\, and no
 vel immune cell-based engager therapeutic discoveries.You will leave this
  meeting with key steps to improving safety and efficacy in the solid tum
 or microenvironment through lower CRS\, greater dose\, and lower TMDD by 
 targeting tumor antigens such as HER2 and EGFR\, and modifying co-stimula
 tory receptors (for example CD137/4-1BB\, CD28).\n\nEnsure your Cell Enga
 ger program reaches full clinical potential through learning from the pio
 neers of immunotherapy.\n
DTEND:20220526T150000
DTSTAMP:20260416T134514Z
DTSTART:20220524T090000
LOCATION:Boston Park Plaza\, 50\, Park Plaza\, Boston\, Massachusetts\, 02
 116\,
SEQUENCE:0
SUMMARY:With TCEs being studied in both hematological and solid tumors (39
  and 34 trials respectively)\, there are now more than one hundred projec
 ts in the...
UID:f7f24f50-4546-497b-8754-8d9e2021e467
END:VEVENT
END:VCALENDAR